Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$28.97 USD
-2.54 (-8.06%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $29.03 +0.06 (0.21%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
CORT 28.97 -2.54(-8.06%)
Will CORT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CORT
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
Other News for CORT
Teva accuses Corcept of monopolizing the market for Korlym
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Teva sues Corcept over alleged mifepristone market monopoly, Reuters says
Analysts Conflicted on These Healthcare Names: Quanterix (QTRX), Corcept Therapeutics (CORT) and Zimmer Biomet Holdings (ZBH)
Corcept Therapeutics Stock Merits Accumulation